Top Markets
#1 EXOD EXOD +56.80%
#2 CoW Protocol CoW Protocol +54.01%
#3 Glidr Glidr +40.55%
#4 Cysic Cysic +38.33%
#5 Walrus Walrus +31.36%
#6 Humanity Humanity +26.19%
#7 Enso Enso +16.12%
#8 Tutorial Tutorial +16.11%
#9 Velvet Velvet +15.00%
#10 Codatta Codatta +14.84%
Coin of the day
EXOD EXOD
設定
言語
日本
通貨
USD
テーマ
DermTech, Inc. DermTech, Inc.

DermTech, Inc.

DMTK
株式のランク #37065
DermTech, Inc., a molecular diagnostics firm headquartered in La Jolla,... DermTech, Inc., a molecular diagnostics firm headquartered in La Jolla, California, specializes in creating and bringing to market advanced, non-invasive genomic tests. Operating within the United States, their innovative solutions facilitate the diagnosis of various dermatological issues, including skin cancer, inflammatory conditions, and age-related skin concerns. A cornerstone of their offerings is the DermTech Melanoma Test (DMT), a sophisticated gene expression analysis. This assay plays a crucial role in enhancing the early identification of genomic abnormalities, effectively aiding in the exclusion of melanoma and often removing the need for invasive surgical biopsies of suspicious pigmented lesions. The company further provides specialized adhesive kits for convenient skin sample collection. Additionally, they offer gene expression assays designed to analyze key inflammatory pathways such, as Th1, Th2, IFN-gamma, and Th17. Looking ahead, DermTech is actively developing a pipeline of new products, which includes DNA risk assessment tools for UV damage, diagnostic tests for non-melanoma skin cancers, and rule-out tests for cutaneous T-cell lymphoma. They also extend their services by delivering health-related information and support through digital and telecommunication platforms. DermTech's diagnostic products and services are primarily targeted towards medical professionals in the fields of pathology and oncology.
株価
$0.069
最終同期: 2024-07-22
時価総額
$2.06M
変化（1日）
-1.43%
変化（1年）
0.00%
国
US
取引 DermTech, Inc. (DMTK)

カテゴリー

Healthcare
DermTech, Inc.（DMTK）の収益
Mar 2024 時点の収益 TTM: $15.66M
DermTech, Inc. の最新の財務報告によると、現在の収益 (TTM) は $15.66M です。2022 年には $14.52M の収益があり、これは 2021 年の $11.84M と比較して 増加 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
DermTech, Inc. の収益履歴（2012 ～ 2026）
各年末の収益
年 収益 変化
2026 (TTM) $15.66M 2.41%
2023 $15.30M 5.36%
2022 $14.52M 22.64%
2021 $11.84M 101.16%
2020 $5.89M 74.94%
2019 $3.36M 0.00%
2018 0.00 0.00%
2017 0.00 0.00%
2013 0.00 0.00%
2012 0.00 0.00%
同業他社の収益
企業 収益 収益の差 国
Thermo Fisher Scientific Inc. Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc.
TMO.US
 $46.34B 295,712.05%
US
Danaher Corporation Danaher Corporation
Danaher Corporation
DHR.US
 $25.11B 160,184.73%
US
WuXi AppTec Co., Ltd. WuXi AppTec Co., Ltd.
WuXi AppTec Co., Ltd.
603259.SS
 - -
CN
Natera, Inc. Natera, Inc.
Natera, Inc.
NTRA.US
 $2.71B 17,182.16%
US
IDEXX Laboratories, Inc. IDEXX Laboratories, Inc.
IDEXX Laboratories, Inc.
IDXX.US
 $4.55B 28,968.07%
US